Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Perimeter Medical Imaging AI shortlisted for grant funding under Biden Cancer Moonshot initiative

Perimeter Medical Imaging AI shortlisted for grant funding under Biden Cancer Moonshot initiative

Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) CEO Adrian Mendes joined Proactive's Stephen Gunnion with news that the company has been shortlisted in a grant funding process sponsored by the Advanced Research Projects Agency for Health (ARPA-H) as part of its Precision Surgical Interventions (PSI) program.

Mendes explained that the initiative aims to provide groundbreaking tools for surgeons to effectively remove cancer in a single operation. Perimeter's technology aligns perfectly with this goal, as they have been working on it for the past decade.

Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) utilizes a technology called OCT, which has been around for 30 years. However, it has developed wide-field OCT, enabling larger image capture crucial for examining excised tumors. The company's current S series device is already in use in several operating rooms, gathering user feedback. It is also conducting clinical trials for its next-gen B series device, integrating AI technology to enhance surgeon workflow.

While the base OCT technology isn't new, the company's innovations and AI integration represent the latest advancements.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK